Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 301

Results For "Patient"

5082 News Found

Lupin receives approval from TGA Australia for Tiotropium Dry Powder
Drug Approval | July 26, 2023

Lupin receives approval from TGA Australia for Tiotropium Dry Powder

Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule


AstraZeneca India receives permission from DCGI for Dapagliflozin
Drug Approval | July 25, 2023

AstraZeneca India receives permission from DCGI for Dapagliflozin

The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca


13.91 crore teleconsultations have been completed:PIB
Policy | July 24, 2023

13.91 crore teleconsultations have been completed:PIB

1. 10 crore teleconsultations have been rendered to senior citizens and 5,22,15,224 to women


Apollo performs 23000+ multi-organ transplantation
Healthcare | July 24, 2023

Apollo performs 23000+ multi-organ transplantation

Apollo Transplant program is the first program in India to cross the landmark of 18500 kidney transplants, 4300 liver transplants and 500 pediatric liver transplants


Lupin receives tentative USFDA’s approval for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets
Drug Approval | July 24, 2023

Lupin receives tentative USFDA’s approval for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets

This product would be manufactured at Lupin's Nagpur facility in India


Lupin launches Luforbec 100/6 for adult asthma and COPD treatment in Germany
News | July 22, 2023

Lupin launches Luforbec 100/6 for adult asthma and COPD treatment in Germany

Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals


Merck receives positive European Union CHMP opinion for Gefapixant
News | July 22, 2023

Merck receives positive European Union CHMP opinion for Gefapixant

The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union


Merck receives positive EU CHMP opinion for pembrolizumab plus Trastuzumab and Chemotherapy as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction
Drug Approval | July 22, 2023

Merck receives positive EU CHMP opinion for pembrolizumab plus Trastuzumab and Chemotherapy as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction

If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU


Tillotts Pharma and TVM Capital form Mage Biologics to develop oral antibody therapy for ulcerative colitis
News | July 21, 2023

Tillotts Pharma and TVM Capital form Mage Biologics to develop oral antibody therapy for ulcerative colitis

Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis